Recombinant Human CD30/TNFRSF8 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11155-CD

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
11155-CD-100
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

P28908.1

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all CD30/TNFRSF8 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human CD30/TNFRSF8 protein
Human CD30
(Phe19-Lys379)
Accession # P28908.1		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Phe19

Predicted Molecular Mass

65 kDa

SDS-PAGE

80-110 kDa, under reducing conditions.

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Human CD30 Ligand/TNFSF8 (Catalog # 1028-CL) is immobilized at 0.2 µg/mL (100 µL/well), Recombinant Human CD30/TNFRSF8 Fc Chimera (Catalog # 11155-CD) binds with an ED50 of 5.00-60.0 ng/mL.

Scientific Data Images for Recombinant Human CD30/TNFRSF8 Fc Chimera Protein, CF

Recombinant Human CD30/TNFRSF8 Fc Chimera Protein Binding Activity.

When Recombinant Human CD30 Ligand/TNFSF8 (1028-CL) is immobilized at 0.2 µg/mL (100 µL/well), Recombinant Human CD30/TNFRSF8 Fc Chimera Protein (Catalog # 11155-CD) binds with an ED50 of 5.00-60.0 ng/mL.

Recombinant Human CD30/TNFRSF8 Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant Human CD30/TNFRSF8 Fc Chimera Protein (Catalog # 11155-CD) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 80-110 kDa and 160-220 kDa, respectively.

Formulation, Preparation and Storage

11155-CD
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CD30/TNFRSF8

CD30, also known as Ki-1 antigen and TNFRSF8, is a 120 kDa type I transmembrane glycoprotein belonging to the TNF receptor superfamily (1, 2). Mature human CD30 consists of a 361 amino acid (aa) extracellular domain (ECD) with six cysteine-rich repeats, a 28 aa transmembrane segment, and a 188 aa cytoplasmic domain (3). In contrast, mouse and rat CD30 lack 90 aa of the ECD and contain only three cysteine-rich repeats. Within common regions of the ECD, human CD30 shares 53% and 49% aa sequence identity with mouse and rat CD30, respectively. Alternate splicing of human CD30 generates an isoform that includes only the C‑terminal 132 aa of the cytoplasmic domain. CD30 is normally expressed on antigen-stimulated Th cells and B cells (4 ‑ 6). However, it is up‑regulated in Hodgkin’s disease (on Reed-Sternberg cells), other lymphomas, chronic inflammation, and autoimmunity (7). CD30 binds to CD30 Ligand/TNFSF8 which is expressed on activated Th cells, monocytes, granulocytes and medullary thymic epithelial cells (1, 5). CD30 signaling co‑stimulates antigen-induced Th0 and Th2 proliferation and cytokine secretion but favors a Th2-biased immune response (8). In the absence of antigenic stimulation, it can still induce T cell expression of IL‑13 (9). CD30 contributes to thymic negative selection by inducing the apoptotic cell death of CD4+CD8+ T cells (10, 11). In B cells, CD30 ligation promotes cellular proliferation and antibody production in addition to the expression of CXCR4, CCL3, and CCL5 (5, 12). An 85 ‑ 90 kDa soluble form of CD30 is shed from the cell surface by TACE-mediated cleavage (13, 14). Soluble CD30 retains the ability to bind CD30 Ligand and functions as an inhibitor of normal CD30 signaling (15).

References

  1. Kennedy, M.K. et al. (2006) Immunology 118:143.
  2. Tarkowski, M. (2003) Curr. Opin. Hematol. 10:267.
  3. Durkop, H. et al. (1992) Cell 68:421.
  4. Hamann, D. et al. (1996) J. Immunol. 156:1387.
  5. Shanebeck, S.D. et al. (1995) Eur. J. Immunol. 25:2147.
  6. Gruss, H.-J. et al. (1994) Blood 83:2045.
  7. Oflzoglu E. et al. (2009) Adv. Exp. Med. Biol. 647:174.
  8. Del Prete, G. et al. (1995) J. Exp. Med. 182:1655.
  9. Harlin, H. et al. (2002) J. Immunol. 169:2451.
  10. Amakawa, R. et al. (1996) Cell 84:551.
  11. Chiarle, R. et al. (1999) J. Immunol. 163:194.
  12. Vinante, F. et al. (2002) Blood 99:52.
  13. Hansen, H.P. et al. (1995) Int. J. Cancer 63:750.
  14. Hansen, H.P. et al. (2000) J. Immunol. 165:6703.
  15. Hargreaves, P.G. and A. Al-Shamkhani (2002) Eur. J. Immunol. 32:163.

Alternate Names

CD30, TNFRSF8

Entrez Gene IDs

943 (Human); 21941 (Mouse); 25069 (Rat)

Gene Symbol

TNFRSF8

UniProt

P28908.1

Additional CD30/TNFRSF8 Products

Product Documents for Recombinant Human CD30/TNFRSF8 Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human CD30/TNFRSF8 Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.